Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON39774
NL-OMON39774
Completed
Not Applicable

Prostate Cancer Molecular Medicine - PCMM

Erasmus MC, Universitair Medisch Centrum Rotterdam0 sites496 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsProstate cancerprostate carcinoma1003859710036958

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prostate cancer
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
496
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • •planned to undergo prostate biopsies according to standard practice
  • •signed informed consent;Group 2:
  • •cT1\-3Nx\-0Mx\-0 prostate cancer
  • •scheduled for radical prostatectomy according to standard practice
  • •signed informed consent

Exclusion Criteria

  • •Group 2 only:
  • •known allergy to contrast agents or sulphur hexafluoride micro bubbles
  • •documented acute prostatitis or urinary tract infections within 8 weeks prior to inclusion
  • •severe cardiac condition
  • •any clinically unstable cardiac condition within 7 days prior to contrast agent administration such
  • •\- evolving or ongoing myocardial infarction
  • •\- typical angina at rest
  • •\- significant worsening of cardiac symptoms
  • •\- recent coronary artery intervention or other factors suggesting clinical instability (e.g., recent
  • •deterioration of ECG, laboratory or clinical findings)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Prostate Cancer Molecular Medicine (PCMM).Prostate cancer / prostaatkanker
NL-OMON27495Erasmus MC, NKI-AvL, UMCG, UMC400
Completed
Not Applicable
Prostate Cancer Molecular Medicine: Transition Grant 2015 (ProCaMolMed)
NL-OMON42675Erasmus MC, Universitair Medisch Centrum Rotterdam525
Active, not recruiting
Phase 1
Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?Metastatic prostate cancerTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2022-003788-13-FIHeikki Minn40
Active, not recruiting
Phase 1
Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?Prostate cancerTherapeutic area: Diseases [C] - Male Urogenital Diseases [C12]
CTIS2024-511104-16-00Turku University Hospital40
Recruiting
Phase 1
Molecular epidemiological analysis of prostate cancer in Hunan populatioprostate cancer
ITMCTR2200005999the First Affiliated Hospital of Hunan University of Chinese Medicine